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T
ype 1 diabetes is an autoimmune disorder char-
acterized by genetic susceptibility associated
with a growing number of loci, including major
histocompatibility complex (MHC), which pro-
vides a strong inﬂuence (1). While the number of suscep-
tibility genes and loci is numerous, an even larger list of
environmental agents has long been noted to inﬂuence, in
either a positive or negative fashion, the risk for or
progression to type 1 diabetes (2). Unfortunately, studies
examining genetic and environmental inﬂuences on type 1
diabetes are remarkably complex in terms of study design,
performance, and data analysis. Large study populations
are also required for identifying minor inﬂuences of ge-
netic loci or environmental agents, yet these efforts often
result in the identiﬁcation of candidates with relatively
small odds ratios (i.e., a small inﬂuence on disease risk). In
addition, type 1 diabetes is quite heterogeneous in its
presentation, form, and characteristics when examined
from either a metabolic or an immunologic perspective. It
is also probable that some degree of complexity arises
from geographical clusters wherein speciﬁc gene-environ-
ment interactions for a particular region yield different
answers to the question of what causes type 1 diabetes (3).
What is evident is that an increase in type 1 diabetes is
occurring globally, yet, as previously emphasized, many
hypotheses exist as to the cause for this observation (4).
Of those thought to be environmental in nature, vitamins
have gained particular attention of late, the most notable
perhaps being vitamin D. This is based on epidemiologic-,
therapeutic-, and genetic-based studies for this molecule
in type 1 diabetes (5–7). At the same time, vitamin A,
another fat-soluble vitamin with immunomodulatory ef-
fects, has been ascribed as being relatively deﬁcient in
subjects with established type 1 diabetes (8). Indeed,
recent studies outside the type 1 diabetes arena have
noted vitamin A as a major “agent of inﬂuence” in the
development of what is widely referred to as “oral toler-
ance” to dietary agents, as well as in the regulation of
immune responses, in general, as shown in Fig. 1 (9).
However, an immediate intellectual conﬂict arises when
attempting to associate these vitamins collectively with
type 1 diabetes risk in that vitamin A deﬁciency is largely
considered a problem in the developing world, whereas
vitamin D deﬁciency is both dietary and latitude inﬂu-
enced. Therefore, it remains to be seen if deﬁciencies of
either of these vitamins actually lead to increased cases of
type 1 diabetes in a uniquely genetic and geographical
way.
Animal studies of type 1 diabetes involving NOD mice
have shown beneﬁcial results with either vitamin A or
vitamin D therapy (10–13). When testing therapeutic inter-
ventions in NOD mice, most studies to date have loosely
been divided into early prevention (in 4- to 8-week-old
mice), late prevention (in 10- to 12-week-old mice), inter-
vention (at diabetes onset), or reversal (in established
diabetes). Broadly speaking, a large number of agents have
shown efﬁcacy in both forms of prevention, with fewer in
intervention, and so far only islet transplantation has
realistically been translated from mice to humans as a
means to intervene in type 1 diabetes (14).
In this issue of Diabetes, Van et al. (15) provide evidence
that a derivative of vitamin A, all-trans retinoic acid
(ATRA), inhibits diabetes formation in NOD mice. This
was essentially demonstrated in two ways. First, the
authors used an accelerated disease model where spleen
cells from already diabetic mice were adoptively trans-
ferred into a strain of mice normally resistant to type 1
diabetes development (i.e., NOD.scid), a system whereby
diabetes is consistently transferred into the recipient mice.
These recipient NOD.scid mice are naturally type 1 diabe-
tes resistant in that while they have the same genetic
background as NOD mice, they have also a mutation that
has rendered them immunodeﬁcient (i.e., no T- or B-
lymphocytes). This makes this strain of animals particu-
larly useful for transferring various cell populations in
order to dissect out contributions of speciﬁc facets of the
immune system to type 1 diabetes progression. Van et al.
(15) demonstrate that by treating NOD.scid recipients with
ATRA, the transfer of diabetes by diabetogenic spleno-
cytes could be markedly suppressed. Their second means
of ascribing efﬁcacy involved demonstration in a “late
prevention” protocol (i.e., using ATRA to treat 10-week-old
NOD mice). In these latter efforts, intraperitoneal injection
of ATRA signiﬁcantly delayed the progression to type 1
diabetes in treated animals.
Armed with these beneﬁcial therapeutic observations,
these authors took their research a step further by pursu-
ing identiﬁcation of the mechanism(s) underlying these
observations, efforts that directed them to notations re-
garding the inﬂuence of ATRA on immunoregulatory path-
ways. In short, they found decreased effector T-cell
function and increased regulatory T-cell activities in asso-
ciation with ATRA treatment. Of further interest, they did
not ﬁnd an effect of ATRA on so-called “Th17 cells,” a
population of cells recently implicated in other (i.e., non-
diabetic) autoimmune disorders (16–18). These Th17 cells
are thought by some (19) to represent the prime mediators
of inﬂammation. Here, it is important to note that while
Van et al. (15) found in vitro evidence that ATRA attenu-
ated Th17 differentiation, the failure to demonstrate this in
vivo requires further investigation. The authors also cor-
rectly point out that in terms of therapy, future studies in
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lished type 1 diabetes must be performed.
So, what does this all mean in terms of human type 1
diabetes? First, the NOD model has been useful in many
investigations, but we have yet to fully translate a preven-
tion or intervention treatment modality from the NOD
mouse to man (note: promising agents do exist but do not
yet form a standard of care). For this reason, it would have
been helpful for Van et al. to have treated the animals with
an oral dose (rather than intraperitoneal injection) that
would approximate tolerable human doses to avoid hyper-
vitaminosis A. Also, this would fall under the category of a
“safe” treatment, with the aforementioned proviso that
vitamin A is toxic in high doses. Finally, both vitamin A
and D are fat soluble and found in ﬁsh oil supplements.
Epidemiological evidence suggests that increased con-
sumption of n-3 fatty acids and ﬁsh oil (which contain
various amounts of vitamin A and D) is associated with
reduced type 1 diabetes–associated autoantibody conver-
sion (20). This raises the intriguing possibility that a
combination of vitamins A and D, in safe pharmacologi-
cally formulated doses rather than the usual daily recom-
mended dose, might be of beneﬁt in the treatment of those
at increased risk for type 1 diabetes. Clearly, more studies
in animal models as well as in humans are required to
validate or disprove this notion.
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FIG. 1. A central role for vitamin A has been proposed in the reciprocal
regulation of inﬂammatory versus regulatory T-cells. Within this
schema, vitamin A suppresses the polarization of Th17 cells while
promoting the induction of T regulatory cells in the context of the
noted cytokines. (Reproduced with permission from Clin Dev Immunol
[DOI 2008:416910], © 2008.)
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